Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VANILLA: Aflibercept in Metastatic Pancreatic Cancer
NCT00574275Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Dec 2007
- Primary completion
- Oct 2009
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial comparing Aflibercept and Gemcitabine with Placebo and Gemcitabine (2 arms). Primary endpoint: Overall Survival at 2 years. Started Dec 2007; status: terminated.
02
Drugs
aflibercept
Beyond the preview
Go deeper on NCT00574275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00574275.